Comparing the Long-term Cost-effectiveness of Repaglinide Plus Metformin Versus Nateglinide Plus Metformin in Type 2 Diabetes Patients with Inadequate Glycaemic Control: An Application of the CORE Diabetes Model in Type 2 Diabetes

References

• Jonsson B. The economic impact of diabetes. Diabetes Care 1998; 21 Suppl 3:C7–10.
   PubMedGoogle Scholar
• Guo JJ, Gibson JT, Gropper DM, Oswald SL, Barker KN. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus. Am J Manag Care 1998; 4(10):1433–46.
   Google Scholar
• Killilea T. Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care. Am J Manag Care 2002; 8(16 Suppl):S441–S449.
   PubMed Web of Science ®Google Scholar
• Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 1994; 78: 809A-F.
   Google Scholar
• Brandle M, Zhou H, Smith BR, Marriott D, Burke R, Tabaei BP, Brown MB, Herman WH. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26(8):2300–4.
   PubMed Web of Science ®Google Scholar
• CCOHTA. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluations of pharmaceuticals: Canada. 2 ed. Ottowa: CCOHTA, 1997.
   Google Scholar
• NICE. National Institute for Clinical Excellence. Guide to the technology appraisal proccess. Available online at http://www.nice.org.uk/pdf/technologyappraisalprocessfinal.pdf (last accessed 4 July 2002).
   Google Scholar
• PBAC. Pharmaceutical Benefits Advisory Committee. Guidelines for the pharmaceutical industry on preparation of submissions to the PBAC, 2002. Available online at http://www.health.gov.au/pbs/pubs/pharmpac/gusubpac.htm (last accessed 7 July 2002).
   Google Scholar
• Sullivan SD, Lyles A, Luce B et al. AMCP guidelines for submission of clinical and economic evaluation data to support formulary listing in the US health plans and pharmacy benefits management organizations. J Managed Care Pharm 2001; 7:272–82.
   Google Scholar
• Detsky AS. Using cost-effectiveness analysis for formulary decision making: from theory into practice. Pharmacoeconomics 1994; 6(4):281–8.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276(15):1253–8.
   Google Scholar
• Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis: Part 1 – Getting started. Med Decis Making 1997; 17(2):123–5.
   Google Scholar
• Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: Part 2 – Building a tree. Med Decis Making 1997; 17(2):126–35.
   Google Scholar
• Stockl K, Vanderplas AM, Nicklasson L. A comparison of costs for four oral antidiabetic regimens within a managed care population. Manag Care Interface 2003; 16(7):31–6.
   Google Scholar
• Ramsdell JW, Braunstein SN, Stephens JM, Bell CF, Botteman MF, Devine ST. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. Pharmacoeconomics 2003; 21(11):819–37.
   PubMed Web of Science ®Google Scholar
• Salas M, Ward A, Caro J. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clin Ther 2003; 24(10):1690–1705.
   Google Scholar
• Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004; 20(Suppl 1):S5–S26.
   PubMedGoogle Scholar
• Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004; 20(Suppl 1):S27–S40.
   PubMedGoogle Scholar
• Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001; 101(6):671–9.
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258):405–12.
   PubMed Web of Science ®Google Scholar
• Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5):383–93.
   PubMed Web of Science ®Google Scholar
• UKPDS Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854–65.
   PubMed Web of Science ®Google Scholar
• UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837–53.
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V and Holman RR for the UKPDS Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281(21):2005–12.
   Google Scholar
• Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging 2000; 17(5):411–25.
   PubMed Web of Science ®Google Scholar
• Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003; 26(7):2063–8.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Labor. Bureau of Labor Statistics. Available online at http://data.bls.gov/cgi-bin/surveymost?cu (last accessed December 9, 2003).
   Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. 1 edn. New York: Oxford University Press, 1996.
   Google Scholar
• UKPDS Group. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabetic Medicine 1998; 15:297–303.
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281(21):2005–12.
   PubMed Web of Science ®Google Scholar
• Baron MA. Comparison of repaglinide and nateglinide in combination with metformin: Response to Raskin et al. Diabetes Care 2003; 26(12):3361–2.
   PubMed Web of Science ®Google Scholar
• Raskin P. Comparison of repaglinide and nateglinide in combination with metformin: Response to Baron. Diabetes Care 2003; 26(12):3362–3.
   Web of Science ®Google Scholar
• Saad MF, Rosenstock J, Hale P, Khutoryansky N. Repaglinide vs. nateglinide monotherapy: a randomized, multicenter, open-label study (Abstract 44). Endocrine Pract 9 (Suppl. 1):17. 2003.
   Google Scholar
• Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000; 23(3):390–404.
   PubMed Web of Science ®Google Scholar
• Harris MI, Cowie CC, Stern MP. Diabetes in America. 2nd edn. Bethesda, Md.: National Institute of Diabetes and Digestive and Kidney Diseases, 1995. (NIH publication no. 95–1468). 1995.
   Google Scholar
• Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24(9):1614–19.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82(8A):2N–9N.
   Google Scholar
• Phillips SJ, Whisnant JP, O’Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990; 65(3):344–59.
   PubMed Web of Science ®Google Scholar
• Miller CD, Phillips LS, Tate MK, Porwoll JM, Rossman SD, Cronmiller N et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 2000; 23(4):444–8.
   PubMed Web of Science ®Google Scholar
• Brandle M, Zhou H, Smith BR, Marriott D, Burke R, Tabaei BP et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003; 26(8):2300–4.
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992; 152(3):610–16.
   Google Scholar
• Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000; 23(6):754–8.
   PubMed Web of Science ®Google Scholar
• Hueston WJ, Scibelli S, Mainous III AG. Use of micro-albuminuria testing in persons with type 2 diabetes: are the right patients being tested? J Fam Pract 2001; 50(8):669–73.
   Google Scholar
• Massing MW, Foley KA, Sueta CA, Chowdhury M, Biggs DP, Alexander CM et al. Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves? Diabetes Care 2003; 26(4):991–7.
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Jacober SJ, Winer N, Kaur J, Castro JP, Wui MA et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002; 25(4):718–23.
   PubMed Web of Science ®Google Scholar